Figitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1 receptor |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9948N1736O2020S54 |
| Molar mass | 146008.04 g·mol−1 |
  (what is this?) (verify) | |
Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]
Anti-cancer mechanism
[edit]See Insulin-like growth factor 1 receptor role in cancer.
Clinical trials
[edit]The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]
It was to have been included in the I-SPY2 breast cancer trial.[8]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
- ^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. (March 2010). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer Chemotherapy and Pharmacology. 65 (4): 765–73. doi:10.1007/s00280-009-1083-9. PMC 2875253. PMID 19649631.
- ^ Gualberto A, Karp DD (July 2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer. 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947.
- ^ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.
- ^ Krauskopf L (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
- ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
- ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
- ^ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
